Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
10374
Millions of yen (year-on-year increase in revenue)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Results presentationQ3 FY20269 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥29,731 million+53.6%
Operating profit¥73 million
Ordinary income¥-1,247 million
Net income¥-2,446 million
Gross Profit Margin60.3%
Operating profit margin0.2%
Selling, general and administrative expenses¥20,601 million
Results for the three months of the current quarterThe results of Ayumi Pharmaceutical for the three months from July to September 2026 were consolidated. Ayumi Pharmaceutical reported revenue of ¥10,836 million and operating profit of ¥1,804 million. The pharmaceutical business's operating margin for July-September was 27.1%.
Full-year earnings forecast
Consolidated revenue
¥47,327 million
Pharmaceutical business
¥40,622 million
Drug Discovery Business
¥177 million
MedTech Business
¥5,647 million
Other Businesses
¥881 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Ayumi Pharmaceutical's contribution to earnings was in line with the company's plan.Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Advisory fees associated with the acquisition of Ayumi Pharmaceutical¥2,030 million
- Expenses related to Gyre’s acquisition of Cullgen as a subsidiary¥481 million
- Share-based compensation expenses for Gyre and Gyre Pharmaceuticals¥1,278 million
- Share-based compensation expenses for Cullgen¥183 million
- Increase in R&D Expenses¥508 million
- Decline in medtech demand due to revisions to the U.S. Medicare system
- Impairment loss on medtech assets¥654 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
USD/JPY155
CNY/JPY21
New initiatives
- Considering measures to strengthen Ayumi Pharmaceutical's production capacity
- Considering increased production using group facilities in China and the United States
- Introduction of the group's pipeline products and biosimilars to Ayumi Pharmaceutical
- Joint promotion and licensing expansion with domestic partners
- Development preparations for the U.S. rollout of F351
- Development aimed at moving 3 degraders into the clinical stage in 2027
Key KPIsA metric the company considers important as a management benchmark.
- Number of employees1,400 people
- Priority Therapeutic Areas6 Area
- Number of pipeline and marketed products38 Products
- Sales network of hospitals and pharmacies21,803 Facilities+
- Number of medical institutions using Ayumi Pharmaceutical products6,347 Facility
- Percentage of medical institutions using Ayumi Pharmaceutical products, rheumatology10.1 %
Segment results
Pharmaceutical business
Revenue
¥24,222 million+107.8%
Operating profit
¥4,089 million+30.9%
Drug Discovery Business
Revenue
¥259 million-65.6%
Operating profit
¥6,443 million
MedTech Business
Revenue
¥4,260 million-29.9%
Operating profit
¥-2,800 million
Other Businesses
Revenue
¥966 million+8.7%
Operating profit
¥-6,925 million
Financial targets
Equity ratio
Results31.4 %
Market Size / Share
- Methotrexate sales share
- Rimachil sales share
- Percentage of rheumatology departments at medical institutions using the products10.1 %
Number of employees
Number of Employees1,400 people
| Item | Details |
|---|---|
| Document type | Results presentation |
| Fiscal Period Covered | Q3 FY2026 |
| Net Sales | ¥29,731 million (YoY +53.6%) |
| Operating profit | ¥73 million |
| Ordinary income | ¥-1,247 million |
| Net income | ¥-2,446 million |
| Gross Profit Margin | 60.3% |
| Operating profit margin | 0.2% |
| Selling, general and administrative expenses | ¥20,601 million |
| Results for the three months of the current quarter | The results of Ayumi Pharmaceutical for the three months from July to September 2026 were consolidated. Ayumi Pharmaceutical reported revenue of ¥10,836 million and operating profit of ¥1,804 million. The pharmaceutical business's operating margin for July-September was 27.1%. |
| Full-year earnings forecast | Consolidated revenue ¥47,327 million / Pharmaceutical business ¥40,622 million / Drug Discovery Business ¥177 million / MedTech Business ¥5,647 million / Other Businesses ¥881 million |
| Self-assessment against the plan | Ayumi Pharmaceutical's contribution to earnings was in line with the company's plan. |
| Segment results | Pharmaceutical business Revenue ¥24,222 million (YoY +107.8%) / Operating profit ¥4,089 million (YoY +30.9%) / Drug Discovery Business Revenue ¥259 million (YoY -65.6%) / Operating profit ¥6,443 million / MedTech Business Revenue ¥4,260 million (YoY -29.9%) / Operating profit ¥-2,800 million / Other Businesses Revenue ¥966 million (YoY +8.7%) / Operating profit ¥-6,925 million |
| Breakdown of Factors Affecting the Change | Factors Advisory fees associated with the acquisition of Ayumi Pharmaceutical / Amount ¥2,030 million, Factors Expenses related to Gyre’s acquisition of Cullgen as a subsidiary / Amount ¥481 million, Factors Share-based compensation expenses for Gyre and Gyre Pharmaceuticals / Amount ¥1,278 million, Factors Share-based compensation expenses for Cullgen / Amount ¥183 million, Factors Increase in R&D Expenses / Amount ¥508 million, Factors Decline in medtech demand due to revisions to the U.S. Medicare system / Amount Not disclosed, Factors Impairment loss on medtech assets / Amount ¥654 million |
| Key KPIs | Indicator name Number of employees / Value 1,400 people / Year on year against the same period last year Not disclosed, Indicator name Priority Therapeutic Areas / Value 6 Area / Year on year against the same period last year Not disclosed, Indicator name Number of pipeline and marketed products / Value 38 Products / Year on year against the same period last year Not disclosed, Indicator name Sales network of hospitals and pharmacies / Value 21,803 Facilities+ / Year on year against the same period last year Not disclosed, Indicator name Number of medical institutions using Ayumi Pharmaceutical products / Value 6,347 Facility / Year on year against the same period last year Not disclosed, Indicator name Percentage of medical institutions using Ayumi Pharmaceutical products, rheumatology / Value 10.1 % / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 1,400 people / Change during the period Not disclosed / Hiring plan Not disclosed |
| Assumptions Underlying the Business Outlook | USD/JPY 155 / CNY/JPY 21 |
| Financial targets | Equity ratio Results 31.4 % |
| Market Size / Share | Indicator Methotrexate sales share / Value Not disclosed, Indicator Rimachil sales share / Value Not disclosed, Indicator Percentage of rheumatology departments at medical institutions using the products / Value 10.1 % |
| New initiatives | Considering measures to strengthen Ayumi Pharmaceutical's production capacity, Considering increased production using group facilities in China and the United States, Introduction of the group's pipeline products and biosimilars to Ayumi Pharmaceutical, Joint promotion and licensing expansion with domestic partners, Development preparations for the U.S. rollout of F351, Development aimed at moving 3 degraders into the clinical stage in 2027 |
Items this document does not state (11)
Progress against full-year forecastUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to the consolidation of Ayumi Pharmaceutical for the July-September period and strong performance in the existing pharmaceutical business. On the earnings front, one-time expenses related to the acquisition of Ayumi Pharmaceutical and the conversion of Cullgen into a wholly owned subsidiary, share-based compensation expenses, and higher research and development expenses weighed on earnings.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.